D. E. Shaw & Co., Inc. Novo Cure LTD Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Novo Cure LTD stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 650,314 shares of NVCR stock, worth $20 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

650,314

Holding current value

$20 Million

% of portfolio

0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$15.61 - $23.34 $764,577 - $1.14 Million	-48,980 Reduced 7.0%	650,314 $10.2 Million
Q2 2024 Aug 14, 2024	SELL	$11.83 - $24.05 $3.01 Million - $6.12 Million	-254,618 Reduced 26.69%	699,294 $12 Million
Q1 2024 May 15, 2024	SELL	$12.42 - $17.29 $5.11 Million - $7.11 Million	-411,405 Reduced 30.13%	953,912 $14.9 Million
Q4 2023 Feb 14, 2024	BUY	$11.13 - $15.78 $11.3 Million - $16 Million	1,013,867 Added 288.48%	1,365,317 $20.4 Million
Q3 2023 Nov 14, 2023	BUY	$16.15 - $42.35 $4.78 Million - $12.5 Million	295,866 Added 532.29%	351,450 $5.68 Million
Q2 2023 Aug 14, 2023	BUY	$40.29 - $82.51 $909,224 - $1.86 Million	22,567 Added 68.35%	55,584 $2.31 Million
Q1 2023 May 15, 2023	BUY	$56.44 - $118.81 $847,559 - $1.78 Million	15,017 Added 83.43%	33,017 $1.99 Million
Q4 2022 Feb 14, 2023	BUY	$63.98 - $85.37 $428,474 - $571,722	6,697 Added 59.25%	18,000 $1.32 Million
Q3 2022 Nov 14, 2022	BUY	$67.99 - $89.57 $318,805 - $419,993	4,689 Added 70.9%	11,303 $859,000
Q2 2022 Aug 15, 2022	SELL	$56.6 - $89.9 $4.44 Million - $7.05 Million	-78,402 Reduced 92.22%	6,614 $460,000
Q3 2021 Nov 15, 2021	SELL	$116.17 - $194.55 $7.56 Million - $12.7 Million	-65,085 Reduced 43.36%	85,016 $9.88 Million
Q2 2021 Aug 16, 2021	BUY	$130.4 - $225.58 $1.98 Million - $3.43 Million	15,185 Added 11.26%	150,101 $33.3 Million
Q1 2021 May 17, 2021	BUY	$124.11 - $190.17 $11.3 Million - $17.4 Million	91,350 Added 209.68%	134,916 $17.8 Million
Q4 2020 Feb 16, 2021	BUY	$112.16 - $174.14 $1.32 Million - $2.05 Million	11,787 Added 37.09%	43,566 $7.54 Million
Q3 2020 Nov 16, 2020	BUY	$58.05 - $111.31 $855,831 - $1.64 Million	14,743 Added 86.54%	31,779 $3.54 Million
Q2 2020 Aug 14, 2020	SELL	$57.2 - $74.41 $1.82 Million - $2.37 Million	-31,885 Reduced 65.18%	17,036 $1.01 Million
Q1 2020 May 15, 2020	SELL	$57.05 - $95.75 $3.27 Million - $5.5 Million	-57,392 Reduced 53.98%	48,921 $3.29 Million
Q4 2019 Feb 14, 2020	SELL	$68.3 - $93.8 $7.49 Million - $10.3 Million	-109,707 Reduced 50.79%	106,313 $8.96 Million
Q3 2019 Nov 14, 2019	SELL	$61.86 - $97.8 $20.5 Million - $32.4 Million	-331,355 Reduced 60.54%	216,020 $16.2 Million
Q2 2019 Aug 14, 2019	SELL	$42.22 - $63.23 $4.62 Million - $6.92 Million	-109,506 Reduced 16.67%	547,375 $34.6 Million
Q1 2019 May 15, 2019	BUY	$31.96 - $56.12 $19.6 Million - $34.5 Million	614,012 Added 1432.3%	656,881 $31.6 Million
Q4 2018 Feb 14, 2019	BUY	$28.72 - $52.63 $1.23 Million - $2.26 Million	42,869 New	42,869 $1.44 Million
Q2 2018 Aug 14, 2018	SELL	$19.85 - $32.0 $996,589 - $1.61 Million	-50,206 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$19.3 - $23.65 $303,376 - $371,754	-15,719 Reduced 23.84%	50,206 $1.09 Million
Q4 2017 Feb 14, 2018	BUY	$16.3 - $21.9 $1.07 Million - $1.44 Million	65,925	65,925 $1.33 Million

Others Institutions Holding NVCR

# of Institutions

263

Shares Held

77M

Call Options Held

1.17M

Put Options Held

318K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.23B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account